BENITEC BIOPHARMA INC (BNTC)
Health Care · Gene therapy / RNA interference therapeutics · NASDAQ
Benitec is a clinical-stage gene therapy company developing DNA-directed RNA interference (ddRNAi) treatments delivered via adeno-associated viral vectors to potentially provide "one-shot" cures for genetic diseases.
What BENITEC BIOPHARMA INC does
Benitec Biopharma is a gene therapy company focused on developing and commercializing DNA-directed RNA interference (ddRNAi) product candidates using adeno-associated viral (AAV) vectors as delivery systems. The company is pursuing a pipeline of clinical and preclinical programs, with revenue primarily derived from licensing and collaboration agreements rather than product sales. Benitec aims to develop therapies that could provide durable or potentially curative treatment effects from a single administration.
Themes: ["Gene therapy","RNA interference / RNAi therapeutics","Genetic disease treatment","One-shot / curative therapeutics","AAV vector technology"]
Fundamentals
- Price$13.48 as of 2026-07-09 close
- Market cap$464M as of 2026-07-10
- 1-year return+6.8% as of 2026-07-09 close
- Net margin-20671.4% as of 2026-07-10
- Gross margin+100.0% as of 2026-07-10
- ROE-45.9% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue CAGR (3y)-93.0% SEC XBRL
- Beta0.26 as of 2026-07-10
Key risks (from latest filing)
["Clinical trial execution risk: timing and sufficiency of patient enrollment, dosing, and trial data availability; regulatory approval uncertainty from FDA","Funding and capital adequacy: ongoing losses, ongoing need for additional financing to execute business plan, and material weakness identified in internal controls over financial reporting","Intellectual property and competitive risk: ability to protect and enforce patents, dependence on collaboration partners, and market acceptance competition"]
Competitors & peers
- Solid Therapeutics
- Sangamo Therapeutics
- REGENXBIO Inc.
- Ultragenyx Pharmaceutical
- Audentes Therapeutics
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.